Mapi Pharma
We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients.
Focus
Our main focus is on developing long acting depot injectable drugs.
Programs
Our lead programs are GA Depot for treating various forms of MS and long acting Pregabalin (Lyrica®) for pain.
Latest News
Mapi Pharma to Present New Safety and Efficacy Data from Glatiramer Acetate Depot Long-Acting Injection Phase II Study in Patients with Primary Progressive Multiple Sclerosis (PPMS) at ACTRIMS Forum 2026
NESS ZIONA, Israel – Feb. 3, 2026 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will present new safety and efficacy data from the GA Depot...
Mapi Pharma is Seeking New Partnerships- Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference
NESS ZIONA, Israel – Jan. 6, 2026 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 44th Annual J.P. Morgan Healthcare...